1 minute reading
1 minute reading
The inspection, conducted by the US Food and Drug Administration between September 19 and 26, found lapses in quality control procedures and the use of an unregistered testing laboratory outside of official facilities.
The USFDA also noted that finished active pharmaceutical ingredients intended for the U.S. market were being released into an off-site warehouse without proper documentation. Other procedural deficiencies were cited, including the failure to record out-of-specification results from the unregistered laboratory, raising questions about the company’s compliance with regulatory standards.
Hetero Labs is a major player in the active pharmaceutical ingredient market and the second largest in the antiretroviral segment. Experts suggest that any escalation in regulatory measures could disrupt supplies to the Nakkapalli plant, potentially benefiting competitors such as Laurus Labs and Aurobindo Pharma.
The market is now closely monitoring Hetero Labs’ Form 483 response and subsequent USFDA actions, which will determine the long-term impact on the company’s operations and supply chain.
(Edited by: Ajay Vaishnav)
Tim BontempsOctober 9, 2025, 11:46 a.m. ETCloseTim Bontemps is a senior NBA writer for ESPN.com who covers the league and…
Former Secretary of Housing and Urban Development Dr. Ben Carson, recently named National Nutrition Advisor at the U.S. Department of…
Federal employees and annuitants are heading into another year of sharp increases in their health insurance premiums, both under the…
A federal judge on Thursday (Oct. 9) dismissed Drake's defamation lawsuit against Universal Music Group over Kendrick Lamar's "Not Like…
10/9: CBS Morning News - CBS News Watch CBS News Israel and Hamas agree to first phase of Gaza peace…
New York Attorney General Letitia James speaks during a news conference January 8, 2025 in New York. Michael M. Santiago/Getty…